GlassScriptPhysician profile
Dara Eileen Schwartz
NPI 1134610959
$3,411.99
in general payments reported to CMS, 2019-2025
29 companies · $1,895 in 2025
The $1,895 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.77 · 2022: $105 · 2023: $31.81 · 2024: $1,292 · 2025: $1,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,041 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,040.74 |
| Education | $178.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $745.80 | 2024-2025 | Fasenra, Tezspire, Airsupra |
| Insmed, INC. | $417.66 | 2024-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $395.59 | 2022-2025 | Trelegy Ellipta, Nucala, Bexsero |
| Actelion Pharmaceuticals US, INC. | $357.62 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Merck Sharp & Dohme LLC | $159.07 | 2024-2025 | Winrevair |
| Amgen INC. | $143.44 | 2021-2025 | Tezspire, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.41 | 2024-2025 | Ofev, Jascayd |
| Vifor Pharma, INC. | $123.43 | 2024-2025 | Zemaira |
| Takeda Pharmaceuticals U.S.A., INC. | $120.45 | 2024-2025 | Glassia, Hyqvia |
| Verona Pharma, INC. | $93.75 | 2025 | Ohtuvayre |
| Abbvie INC. | $91.97 | 2021-2024 | |
| Pulmonx Corporation | $87.73 | 2024-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| United Therapeutics Corporation | $77.43 | 2024-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $63.78 | 2024 | Yupelri |
| Baxter Healthcare | $60.71 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $60.34 | 2024-2025 | Smartvest |
| Grifols USA, LLC | $33.36 | 2025 | Prolastin-C Liquid |
| Currax Pharmaceuticals LLC | $28.10 | 2022-2023 | Contrave, Onzetra Xsail |
| Novartis Pharmaceuticals Corporation | $27.38 | 2025 | |
| Inspire Medical Systems, INC. | $25.94 | 2024 | Inspire |
| Mallinckrodt Hospital Products INC. | $23.41 | 2025 | Acthar |
| Lilly USA, LLC | $21.28 | 2024 | Mounjaro |
| Viatris Specialty LLC | $20.73 | 2025 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.37 | 2021 | |
| Exact Sciences Corporation | $18.33 | 2023 | Cologuard Collection Kit |
| Philips North America LLC | $18.04 | 2025 | Vest Therapy Und |
| Inogen, INC. | $17.23 | 2024 | |
| Novo Nordisk INC | $17.03 | 2025 | |
| Dexcom, INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dara Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.